NeuroSense Seeks US Patent for PrimeC in Traumatic Brain Injury
NeuroSense Therapeutics has filed a U.S. patent application for PrimeC's ciprofloxacin and celecoxib combination in brain injury, protection to 2047 if granted.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
NeuroSense Therapeutics has submitted a patent application to the US Patent and Trademark Office for treating brain trauma with a mix of ciprofloxacin and celecoxib, the two active ingredients in its drug PrimeC. Reuters and TradingView both reported the filing, citing the company's announcement. The claim would cover conditions from concussion and mild injuries to severe TBI, blast injuries and chronic traumatic encephalopathy. If a patent is granted, protection would run through 2047, subject to extensions. The company says ALS remains its main development priority.
why it matters
For markets this is a modest step. The filing widens the possible uses of PrimeC beyond ALS but does not confirm a granted patent or any new trial data. Small biotechs like NeuroSense tend to trade on clinical results and funding news, and the company's own disclosures list financing and Nasdaq compliance among its risks.
tags
instruments
sources
- NeuroSense Files U.S. Patent Application for Traumatic Brain Injury — TradingView, 19 October 2026 at 12:25 UTC
- Neurosense Files US Patent Application For Traumatic Brain Injury — Reuters, 19 October 2026 at 13:06 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗